Immunomedics, Inc’s (NASDAQ:IMMU) Shares tumbled over 15% As Second Quarter’s Loss Widens Print
By David Fowler   
Thursday, 05 February 2015 13:26

Shares of Immunomedics, Inc.(NASDAQ:IMMU) are under heavy selling pressure on Thursday and tumbled as much as 15.50% to $4.12 following the company has reported second-quarter loss.

The company posted a net loss of $11.4 million, or 0.12 cents for the latest quarter, compared to a year a ago loss of $8.5 million, or 10 cents a share. However, this topped analysts’ forecast of a loss of 13 cents a share by Zacks.

Revenue during the second quarter stood at $1.0 million, down from a year ago revenue of $1.2 million. The decrease of $0.2 million in total revenues this quarter was primarily the result of $0.2 million decline in LeukoScan sales volume in Europe.

Total costs and expenses during the quarter jumped to $12.5 million, from $9.8 million for the same period in 2014, an increase of $2.7 million or 28%. This increase was driven primarily by $3.2 million increased research and development expenses from higher clinical trial cost for, in particular, the Phase 3 PANCRIT-1 registration study of yttrium-90-labeled clivatuzumab tetraxetan for the therapy of patients with advanced pancreatic cancer. The increase in research and development expenses was partially offset by a $0.2 million lowered legal and professional expenses.

Shares of the company are down over 11% for the past one year. Over the past one year, shares of IMMU have been trading within a range of $3.04-$4.60. The mean target set by 2 analysts is $7 on the stock.

Additionally, the company announced its plan of offering $85,000,000 aggregate principal amount of Convertible Senior Notes due 2020 in a private placement.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!